| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 15, 2024 |
| Accession Number: | 0001140361-24-043041 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/22/2021 | $6.00 | Outperform | Oppenheimer |
| 12/21/2021 | $6.00 | Outperform | Oppenheimer |
4 - Acasti Pharma Inc. (0001444192) (Issuer)
3/A - Acasti Pharma Inc. (0001444192) (Issuer)
3 - Acasti Pharma Inc. (0001444192) (Issuer)
4/A - Acasti Pharma Inc. (0001444192) (Issuer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Acasti Pharma Inc. (0001444192) (Filer)
EFFECT - Acasti Pharma Inc. (0001444192) (Filer)